Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
VLP, as a delivery system for cancer vaccines, helps trigger effective immune responses, ensure safety, and enable the development of more effective and targeted cancer immunotherapies. Alfa Cytology provides VLPs delivery systems development service as part of the cancer vaccine development platform, hoping to develop more effective and targeted immunotherapies.
VLPs typically have a complete envelope or capsid but do not contain genetic material. Genetic engineering methods can be used to insert antigen sequences into the sequence of envelope proteins, or they can be directly covalently conjugated to the surface of VLPs. VLP uses biomimetic mechanisms to stimulate immune responses and delivers cancer antigens by mimicking certain characteristics of the virus. Although VLP contains virus-related proteins, it cannot replicate and does not cause infectious diseases. Therefore, it has many advantages as a delivery system for cancer vaccines.
Safety
The structure and characteristics of VLP and virus particles are very similar, but they cannot replicate or cause diseases. They can trigger an immune response without the risk of actual viral infection.
Stability
The VLP particle size is uniform and stable, which allows antigen-presenting cells (APCs) to easily uptake and effectively deliver the antigen to the immune system.
Immunogenicity
Due to its structural similarity to viruses, VLP has high immunogenicity and can induce strong and specific immune responses. VLP itself also exhibits certain adjuvant properties.
Multivalent Display
VLP can be designed to display multiple copies of antigen peptides or proteins, thereby achieving multivalent epitope presentation. It enhances the cross-linking of immune receptors on immune cells.
VLP is engulfed and processed by dendritic cells (DC), presenting tumor antigens to major histocompatibility complexes (MHC-I and MHC-II) for recognition by CD8+ and CD4+ T cells. CD4+ T cells differentiate into T helper cells, i.e., TH2 and TH1 cells, which participate in the inflammatory response and maintain the activity of CD8+ T cells, i.e., cytotoxic T cells, respectively.
Fig. 1 VLPs delivery system workflow diagram.
The numerous advantages of VLP make it an ideal choice for vaccine delivery, Alfa Cytology provides diversified VLPs delivery systems development services. We offer three different types of VLPs based on their different structures. In addition, based on cost and other requirements, we also provide various expression systems for the production and modification of VLP, including yeast, bacteria, mammalian cells, insect cells, etc.
Professional
technical team.
Advanced experimental equipment.
Empowering success through cooperation.
Strict quality control system.
Alfa Cytology is committed to solving various problems in the field of cancer vaccines and has in-depth and extensive development experience. VLPs delivery system is often used together with the protein cancer vaccine or peptide cancer vaccine. If you are interested in our service, please contact us for more details.